Study suggests gasdermin D inhibition may protect mice by blocking release of cellular contents into the extracellular ...

Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...

Early research shows that editing expanding trinucleotide repeats halts the lengthening process that causes neurological ...

Proteins represent 95% of drug targets designed to combat disease, according to Yvonne Tan, PhD, from Nuclera.

A scientist says he has shown that it’s possible to produce a large amount of virus-like particles using a fully scalable ...

Using neem tree extracts as a starting point, scientists have created several kinds of nanozymes and tested them for ...

T therapies is an expensive business. The fundamental problem is that CAR-T production is not a good fit for centralized manufacturing.

Single-use continuous bioprocessing can reduce mAb production costs and shorten time-to-market compared to batch processing.

Wacker and Expression Manufacturing want to offer clients with an end-to-end, optimized solution for viral vector development and production.

How CD4+ T cells respond to Chikungunya virus may trigger long-lasting joint pain, mimicking autoimmune disease long after infection clears.

The first systematic genome-wide association study for pseudogout has identified two genes strongly associated with disease progression.

Rocket Pharmaceuticals acknowledged the death of a patient in a pivotal trial assessing its Danon disease gene therapy candidate RP-A501, a study that the FDA has placed on clinical hold.